Saturday, October 31, 2026

ZoomInfo Stock Bearish By 27% In The Last 21 Sessions

ZoomInfo Stock Bearish By 27% In The Last 21 Sessions

ZoomInfo Technologies Inc. (NASDAQ: ZI) is a leading go-to-market intelligence and sales engagement service provider that recently experienced significant market turbulence. The entity saw an astounding 27.08% decline over 21 trading sessions, falling from $0.48 on July 5, 2023, to just.58 as Thursday ended. It's worth noting that this marked three straight sessions of losses for ZoomInfo.

NASDAQ and its relevance to ZoomInfo's performance

This development closely parallels NASDAQ, which experienced a modest decline of 0.12% to close at $956.57 and post its second consecutive session of losses. It's important to mention that ZoomInfo's most recent closing position stood at.40, representing a decrease of 64.52% compared to its 52-week high of.86 which provides a fuller context to the company's performance detractors.

Understanding ZoomInfo's Operational Terrain

ZoomInfo operates across a wide array of verticals - from software, business services and manufacturing to telecom, financial services, retail media & internet, transportation education hospitality & real estate. This not only demonstrates its capacity for resilience and adaptability in ever-evolving market conditions but also shows ZoomInfo's ability to pivot in response to shifting environments.

ZoomInfo's Financial Indicators

ZoomInfo boasts a trailing twelve months (TTM) earnings per share (EPS) of 0.25. Coupled with its price-to-earnings (PE) ratio at 74.32, each dollar of its annual earnings would cost investors $0.32, making this stock more of a growth stock than a value option. However, at only 4.64% for the last twelve months, this firm's modest return on equity (ROE) raises further questions regarding its efficiency at turning shareholder equity into profits.

ZoomInfo's Trading Position

It's significant to note that ZoomInfo continues to trade below its 50-day and 200-day moving averages of.87 and.33 respectively, which suggests further weakness. Indeed, recent performance and market indicators seem to signal an unstable period for ZoomInfo shareholders.

Despite this, market behavior remains unpredictable, and only time will tell whether ZoomInfo's wide operational terrain can help it weather economic fluctuations successfully. Observers and investors should keep a close eye on this space for updates.

More news about ZoomInfo (ZI).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com